134 related articles for article (PubMed ID: 7554780)
1. The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients.
Lithner F; Bergenheim T; Borssén B; Dahlén G; Nilsson TK
Diabet Med; 1995 Jul; 12(7):590-4. PubMed ID: 7554780
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis and diabetic retinopathy in NIDDM.
Mansfield MW; Grant PJ
Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
[TBL] [Abstract][Full Text] [Related]
4. Does chronic smoking influence fibrinolytic potential in type 1 diabetes mellitus?
Simpson AJ; Booth NA; Moore NR; Gray RS
Diabet Med; 1998 Aug; 15(8):683-7. PubMed ID: 9702473
[TBL] [Abstract][Full Text] [Related]
5. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
[TBL] [Abstract][Full Text] [Related]
6. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
7. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
8. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
Diabetes Res Clin Pract; 1994 Jan; 22(2-3):123-8. PubMed ID: 8200293
[TBL] [Abstract][Full Text] [Related]
9. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
[TBL] [Abstract][Full Text] [Related]
10. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
Vicari AM; Viganó D'Angelo S; Testa S; Comi G; Galardi G; Orsi E; D'Angelo A
Horm Metab Res; 1992 Nov; 24(11):516-9. PubMed ID: 1452117
[TBL] [Abstract][Full Text] [Related]
11. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol.
Jansson JH; Johansson B; Boman K; Nilsson TK
J Intern Med; 1991 Apr; 229(4):309-16. PubMed ID: 1902868
[TBL] [Abstract][Full Text] [Related]
12. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
Rautio A; Boman K; Eriksson JW; Svensson MK
Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
[TBL] [Abstract][Full Text] [Related]
13. Impaired vibration perception threshold and long-term mean HbA1c in patients with type 1 diabetes mellitus.
Kullberg CE; Arnqvist HJ
Diabet Med; 1996 Dec; 13(12):1027-32. PubMed ID: 8973883
[TBL] [Abstract][Full Text] [Related]
14. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
15. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Zitoun D; Bara L; Basdevant A; Samama MM
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
[TBL] [Abstract][Full Text] [Related]
16. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
Gough SC; Rice PJ; McCormack L; Chapman C; Grant PJ
Diabet Med; 1993; 10(7):638-42. PubMed ID: 8403825
[TBL] [Abstract][Full Text] [Related]
17. Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications Study.
Maser RE; Ellis D; Erbey JR; Orchard TJ
J Diabetes Complications; 1997; 11(4):243-9. PubMed ID: 9201602
[TBL] [Abstract][Full Text] [Related]
18. Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
Hernestål-Boman J; Norberg M; Jansson JH; Eliasson M; Eriksson JW; Lindahl B; Johansson L
Cardiovasc Diabetol; 2012 Dec; 11():152. PubMed ID: 23249721
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Johansson L; Jansson JH; Boman K; Nilsson TK; Stegmayr B; Hallmans G
Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711
[TBL] [Abstract][Full Text] [Related]
20. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
